Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.
Claire GalloisMatteo LandiGilles ManceauMarine SroussiBahar Saberzadeh-ArdestaniAntoine CazellesSara LonardiFrancesca BergamoRossana IntiniGiulia MaddalenaFilippo PietrantonioFrancesca CortiMargherita AmbrosiniAntonia MartinettiMarco Maria GermaniChiara BoccaccioGuglielmo VetereSophie Mouillet-RichardAurélien de ReynièsFrank A SinicropeChiara CremoliniPierre Laurent-PuigPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
This unsupervised transcriptomic classification identified three groups of MSI mCRCs with different compositions of TME cells and proliferative capacities of TME/tumor cells. The "stromalHIGH-proliferationLOW" cluster is associated with a poorer prognosis with ICI treatment.